Dosimetry from organ to cellular dimensions.
While the conventional Medical Internal Radiation Dose (MIRD) approach is useful for estimating approximate organ absorbed doses in diagnostic applications of isotopes, this strategy is suited neither to the exacting requirements of targeted radionuclide therapy nor to radiopharmaceuticals with a non-uniform activity distribution. For the individual treatment planning of patients treated with common radionuclides emitting high energy betas, the individual activity distribution has to be obtained from CT-SPECT images and the doses to the target organs and critical tissues have to be calculated by point-kernel methods. Due to the stochastic nature, alpha-radioimmunotherapy (alpha-RIT) requires microdosimetric calculations with Monte Carlo on a realistic model of the source and target tissue at the micrometer level. For a prediction of the biological effects of intracellular labelling with Auger electron emitters an accurate subcellular modelling including the DNA structure at the nanometre level with knowledge of the target for the considered biological effect is necessary.
Thierens
H M
HM
Department of Biomedical Physics and Radiation Protection, University of Ghent, Proeftuinstraat 86, B-9000 Gent, Belgium. hubert.thierens@rug.ac.be
Monsieurs
M A
MA
Brans
B
B
Van Driessche
T
T
Christiaens
I
I
Dierckx
R A
RA
D019797:3-Iodobenzylguanidine / Q000627:therapeutic use; D000512:Alpha Particles / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000493:pharmacokinetics / Q000627:therapeutic use; D001610:Beta Particles / Q000627:therapeutic use; D001853:Bone Marrow / Q000528:radiation effects; D002477:Cells / Q000528:radiation effects*; D003198:Computer Simulation; D005260:Female; D006801:Humans; D018499:Linear Energy Transfer; D008297:Male; D009010:Monte Carlo Method; D009447:Neuroblastoma / Q000000981:diagnostic imaging / Q000532:radiotherapy; D011237:Predictive Value of Tests; D016499:Radioimmunotherapy / Q000592:standards; D011874:Radiometry / Q000379:methods* / Q000592:standards*; D019275:Radiopharmaceuticals / Q000493:pharmacokinetics / Q000627:therapeutic use; D011878:Radiotherapy / Q000592:standards*; D014018:Tissue Distribution; D015899:Tomography, Emission-Computed, Single-Photon; D014057:Tomography, X-Ray Computed
D000970:Antineoplastic Agents; D019275:Radiopharmaceuticals; D019797:3-Iodobenzylguanidine